Menu
Recruiting NCT05647044

Frontal iTBS for Impulsivity and Suicidal Ideation in Veterans With Mild Traumatic Brain Injury

Phase I Interventional Mild Traumatic Brain Injury Suicidal Ideation Impulsivity

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: intermittent theta burst stimulation, placebo intermittent theta burst stimulation.
Who it may be relevant to
Registry conditions: Mild Traumatic Brain Injury, Suicidal Ideation, Impulsivity. Basic parameters: 22 years — 65 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Neuromodulation for Impulsivity and Suicidality in Veterans With Mild Traumatic Brain Injury and Common Co-occurring Mental Health Conditions

Overview

The investigators hope to develop a treatment for suicidal ideation (SI), impulsivity and functional impairments (such as difficulties in social and work settings) that occur after a mild traumatic brain injury (mTBI). These conditions have been shown to be linked. The investigators are using a high-powered magnetic pulse, called intermittent theta burst stimulation (iTBS) applied to the head to see if it can improve these symptoms. The high-powered magnetic pulse causes certain cells in the brain to activate, which seems to strengthen connections between parts of the brain. The purpose of this research is to gather early information on the safety and effectiveness of iTBS provided to the front of the head for impulsivity, SI and functional deficits after mTBI. The investigators plan to use the data collected in this study to develop larger studies in the future. iTBS is FDA approved, but not for these specific symptoms, or in the specific location the investigators are placing it. The investigators are testing to see if its effective for the above conditions when applied to the front of the head.

Detailed description

Individuals with mild traumatic brain injury (mTBI) are at increased risk of dying by suicide compared to those without - both among Veteran and civilian populations. 22% of Veterans with mTBI report struggling with suicidal ideation (SI). Despite this, there are no effective evidence-based treatments for co-occurring mTBI and SI. Deficits in social and occupational functioning, which often follow mTBI, are strongly related to suicidal ideation (SI) and improvements in these areas are known to lessen SI. Thus, improving function for those with mTBI and SI is of great potential significance. The impulsivity that Veterans with mTBI exhibit is referred to as "negative urgency impulsivity". It often involves aggressive and self-harming behaviors, which impede societal re-integration and rehabilitation. Prior studies indicate negative urgency impulsivity is: (1) a common TBI sequela and (2) a risk factor for SI. Previous studies have also indicated individuals with TBI, SI and negative urgency impulsivity had reduced right-sided ventromedial prefrontal cortex (VMPFC) volume compared to Veterans without these conditions. The VMPFC plays a key role in controlling impulsive limbic responses. These findings are consistent with published reports suggesting individuals with reduced VMPFC volume are more likely to (a) have SI and (b) behave impulsively.

Transcranial magnetic stimulation (TMS) holds significant therapeutic promise for post-mTBI SI, impulsivity and functional deficits. TMS induces neuroplasticity, leading to changes that have the potential to improve neurorehabilitation outcomes. TMS is effective for treating post-TBI depression when administered to the dorsolateral prefrontal cortex. Intermittent theta burst stimulation (iTBS) is a "second generation" form of TMS that is delivered more rapidly. It has been proposed that frontal pole TMS could directly strengthen connections throughout the prefrontal cortex, including the VMPFC, thereby dampening limbic system activity. Such a TMS treatment strategy could be used to treat post-mTBI impulsivity and SI, ultimately allowing Veterans to regain functioning. It is not know which Veterans would benefit most from this treatment; examining neural connectivity changes before and after iTBS could determine who would respond to frontal pole iTBS and why.

The investigators will conduct a randomized, double-blinded frontal iTBS pilot clinical trial for Veterans with mTBI, impulsivity and SI. As this is a novel treatment approach for this population, this project will focus on testing the safety, feasibility and tolerability of frontal pole iTBS. To inform future research, this project will determine the preliminary effects of iTBS on functioning, negative urgency impulsivity and SI among the pilot sample. This project will also inform future research by examining the relationships between the functional neural connectivity of the VMPFC to the limbic system and how this is affected by iTBS using resting state functional connectivity (rsFC) neuroimaging data, pre- and post-iTBS.

Interventions

  • Device intermittent theta burst stimulation
    intermittent theta burst stimulation (iTBS) will be delivered with the Magventure MagProX100 with MagOption stimulation and Magpro Cool Coil B65 A/P. The Magpro Cool Coil B65 A/P can be switched to active or placebo. The Magventure C-B60 coil will be used to deliver single TMS pulses for motor threshold determination.
  • Device placebo intermittent theta burst stimulation
    intermittent theta burst stimulation (iTBS) will be delivered with the Magventure MagProX100 with MagOption stimulation and Magpro Cool Coil B65 A/P. The Magpro Cool Coil B65 A/P can be switched to active or placebo. The Magventure C-B60 coil will be used to deliver single TMS pulses for motor threshold determination.

Primary outcome measures

  • Session Completion Rate [Time frame: Endpoint - after last iTBS session, approximately 2 weeks]
  • Change in Social and Occupational Functioning Assessment Scale (SOFAS) [Time frame: Rated at baseline, study midpoint (at the end of week 1) and study completion, approximately 2 weeks after study begins]
Secondary outcome measures (1)
  • Change in Columbia Suicide severity rating scale (C-SSRS) [Time frame: Rated at baseline, study midpoint (at the end of week 1) and study completion, approximately 2 weeks after study begins.]

Eligibility criteria

Inclusion criteria

  • 22-65 years of age
  • can read and speak English
  • meets criteria for mTBI according to the symptom attribution and classification (SACA) scale
  • Has a C-SSRS (suicidal ideation rating) of >1 within the past month
  • Has a history of impulsivity documented in the medical chart and/or a score of >20 on the UPPS-P negative urgency impulsivity subscale

Exclusion criteria

  • Has contraindications to iTBS (i.e., epilepsy)
  • Has contraindications to MRI (i.e., claustrophobia, ferromagnetic metal implants)
  • Has an active substance use disorder per the DSM-V criteria
  • Has a history of moderate to severe TBI
  • Has a history of non-traumatic neuroinjury (i.e., stroke, neurosurgery, hemorrhage)
  • Has a history of, or current psychosis not due to an external cause
  • Is pregnant
  • Has an active, unstable medical condition
  • Is within 12 weeks of a major surgery or operation
  • Is within 1 year of TBI

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Quadruple blind
Primary purpose
Treatment

Study locations

United States · 1 center
  • Edward Hines Jr. VA Hospital, Hines, IL — Hines

Publications

  • Bernanke A, Hasley R, Sabetfakhri N, de Wit H, Smith BM, Wang L, Brenner LA, Hanlon C, Philip NS, Ajilore O, Herrold A, Aaronson A. Frontal Pole Neuromodulation for Impulsivity and Suicidality in Veterans With Mild Traumatic Brain Injury and Common Co-Occurring Mental Health Conditions: Protocol for a Pilot Randomized Controlled Trial. JMIR Res Protoc. 2024 Dec 13;13:e58206. doi: 10.2196/58206. PMID 39671573

Identifiers

NCT: NCT05647044 · D4298-W

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗